Pneumonic plague cluster, Uganda, 2004.

The public and clinicians have long-held beliefs that pneumonic plague is highly contagious; inappropriate alarm and panic have occurred during outbreaks. We investigated communicability in a naturally occurring pneumonic plague cluster. We defined a probable pneumonic plague case as an acute-onset respiratory illness with bloody sputum during December 2004 in Kango Subcounty, Uganda. A definite case was a probable case with laboratory evidence of Yersinia pestis infection. The cluster (1 definite and 3 probable cases) consisted of 2 concurrent index patient-caregiver pairs. Direct fluorescent antibody microscopy and polymerase chain reaction testing on the only surviving patient's sputum verified plague infection. Both index patients transmitted pneumonic plague to only 1 caregiver each, despite 23 additional untreated close contacts (attack rate 8%). Person-to-person transmission was compatible with transmission by respiratory droplets, rather than aerosols, and only a few close contacts, all within droplet range, became became ill.

**********

Naturally occurring plague occurs most frequently in bubonic or septicemic forms and is usually acquired through the bite of an infected rodent flea. Bubonic and septicemic plague are not transmissible from person to person, but if left untreated, plague bacteria can spread hematogenously to the lungs, resulting in secondary pneumonic plague. Pneumonic plague is contagious through infectious respiratory secretions, potentially resulting in direct airway infection (primary pneumonic plague) among close contacts (1,2).

Pneumonic plague epidemics in China early in the 20th century killed tens of thousands of persons (3). Plague is now rare in developed countries. However, the possibility of an intentional aerosol release of plague bacteria causing numerous contagious primary pneumonic plague cases has been a top concern of bioterrorism specialists (1). Consequently, Yersinia pestis release scenarios have been used in large-scale bioterrorism preparedness drills (4,5). The possibility of pneumonic plague importation's causing an outbreak in a nonendemic region is also a concern (6).

In-country panic and international alarm followed the 1994 report of pneumonic plague in India (7). Physicians reportedly fled Surat, the affected city, stating that there was "nothing to be done," and tetracycline was hoarded in areas distant from the reported outbreak (7). Some commercial airline flights (8) and exports (7) from India were cancelled. English physicians contested their public health officials' description of plague's low communicability based on their clinical training and infectious disease textbooks (9). Commercial repercussions for India have been estimated at US $3-$4 billion (7). Similarly and more recently, thousands fled a suspected pneumonic plague outbreak in the Congo during 2005 (10).

The public and clinicians have long-held beliefs that pneumonic plague is highly communicable (9,11-13). The current Infectious Diseases Society of America (IDSA) summary on Y. pestis as a bioterrorism agent notes secondary transmission risk is not well-quantified (14). Because of its rarity, recent published observations on its contagiousness are scarce, and few clinicians have first-hand knowledge of the disease.

We describe pneumonic plague's communicability and clinical course in a recently investigated cluster. On December 26, 2004, a Ugandan police officer telephoned a local physician (author G.A.) about a cluster of deaths in that country's West Nile region. The physician initiated an investigation that day and was joined the next day by US Centers for Disease Control and Prevention (CDC) staff who were in the area for a plague treatment trial.

Methods

The surviving patient, caregivers and healthcare providers of the ill, and other close contacts of the deceased were interviewed to understand how the outbreak was propagated and to identify close contacts needing prophylaxis. The surviving patient's clinicians (G.A. and Z.A.) provided clinical information. Because CDC and the Ugandan Ministry of Health were conducting a plague treatment trial in the area, prospective enhanced surveillance for plague was already ongoing in the West Nile region, involving at least weekly local health center visits. For this enhanced surveillance, a probable bubonic plague case was defined as an illness with fever and tender lymphadenopathy without another cause for lymphadenopathy (e.g., cellulitis or streptococcal pharyngitis). For this cluster investigation, we conducted additional retrospective pneumonic plague surveillance by interviewing private drug shop owners, business owners, traditional healers, and other area residents. We defined a probable pneumonic plague case as respiratory illness of acute onset with cough producing grossly bloody sputum during December 2004 in Kango Subcounty, Nebbi District, Uganda. For this investigation, we defined a definite pneumonic plague case as a probable case with laboratory evidence of plague infection.

Laboratory Methods

The surviving patient's sputum and serum samples were tested for direct and indirect evidence of plague infection. Sputum was placed on blood agar plates to recover live organisms, tested by polymerase chain reaction (PCR) for evidence of Y. pestis DNA, reacted with fluorescent-labeled antibody specific for Y. pestis and analyzed by fluorescent microscopy, and assessed for E pestis antigen by using 2 handheld immunochromatographic assays (i.e., dipsticks) (TetraCore, Inc., Gaithersburg, MD, USA, and New Horizons, Columbia, MD, USA). Serum samples collected during the acute phase of the disease were tested for antibody to F 1 antigen of Y. pestis (15).

Extraction of DNA and PCR

The genes caf1, repA1, and pla were analyzed by PCR. CDC has used these primers for many years for recognition of Y. pestis DNA. Primer sequences were caf1-f 5'-ATACTGCAGATGAAAAAAATCAGTTCC-3', caf1-r 5'-ATAAAGCTTTTATTG GTTAGATACGGT- 3'; repA1-f 5'-AGGCCCTGTTCACACATC-3', repA1-r 5'-CCGGG TGTA GTTATTGTTCC-3"; and pla-f5"-ATCTTACTTTCCGTGAGAA-3', pla-r 5'-CTTGGATGTTGA GCTTCCTA-3'. Basic local alignment and sequencing tool analysis against all known sequences in GenBank demonstrated no significant homologies outside Y. pestis for car1 and pla primers. The repA1 primer set also has 100% homology to Y. pestis, Y. pseudotuberculosis, and Y. enterocolitica. DNA was extracted from 200 [micro]L of sputum by using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) and manufacturer's protocol. A total of 5 [micro]L extracted DNA from the sputum or a positive control (Y. pestis strain CO 92) or negative control (water) was added to each reaction. PCR conditions were as previously described (16). Expected amplicon sizes were 531 bp (caf1), 833 bp (repA1), and 480 bp (pla). PCR was carried out by using puReTaq Ready-To-Go PCR Beads (Amersham Biosciences, Piscataway, NJ, USA).

Direct Fluorescent-Antibody Test

Sputum was vigorously vortexed to disrupt the semisolid mass, then centrifuged at 8,000 x g for 5 min to pellet the solid material. The pellet was washed once in phosphate-buffered saline (PBS) and resuspended in 75 [micro]L of PBS. Approximately 5 [micro]L of concentrated sputum was used for direct fluorescent-antibody (DFA) microscopy as previously described (17) and visualized at 400x magnification.

Results

Cluster Description

We identified 1 definite and 3 probable pneumonic plague cases, comprising 2 concurrent index patient-caregiver pairs. We refer to the pairs as A and B, with numbers 1 and 2 designating index and caregiver cases within each pair, respectively. Index patient B 1 became ill 1 day before cough onset in index patient A1. Despite extensive investigation, we identified no social links between these 2 index patients and no evidence of contact in the week before patient A1's illness onset. We identified no other illnesses clinically compatible with pneumonic plague occurring in December 2004 in Kango Subcounty by active surveillance. All case-patients' disease symptoms are shown by onset day in the Table. Overall, compared with index patients, caregivers' illnesses progressed more rapidly, including quicker bloody sputum onset (mean 1 vs. 6 days).

Index patient A1 was a 22-year-old woman, and her primary caregiver, patient A2, was her 40-year-old mother. According to family members, patient A1's illness began with several days of headache, fever, and chills. Lymphadenopathy was first observed on day 3. Coughing, first noted on day 5, became productive a day later and bloody sputum was noted on day 7. On day 6, she was seen by a drug shop owner (a government-trained nursing assistant) and treated for malaria with 3 days of chloroquine. On day 9, she was coughing frank blood and died later that night. Patient A1's primary caregiver, patient A2, became ill 5 days after her daughter's death. On the first day of patient A2's illness, she reported headache, fever, chills, weakness, chest pain, and a productive cough. The same private drug shop owner examined her and reported ulcerative pharyngitis, a sign associated with inhalational exposure to Y. pestis (12), but not lymphadenopathy. The patient was treated with intramuscular penicillin (6 treatments over 36 h) for presumptive severe pneumonia. The next day grossly bloody sputum developed, and she died on illness day 3.

Index patient B1 was a 25-year-old man, and his primary caregiver, patient B2, was his 30-year-old sister. Index patient B1's illness began with headache, fever, and chills. His family sought care for him at a private drug shop and transported him to 3 government health centers. Lymphadenopathy was not reported, although his clinicians did not specifically examine him for it. He received antimalaria treatment and intramuscular penicillin for presumptive severe pneumonia. His cough became productive with bloody sputum on day 5 of illness, and he died on day 6. Patient B1's primary caregiver, B2, became ill 5 days after patient B1's death.

Surviving caregiver B2 was identified the day the outbreak was reported, a day after her illness onset. She was markedly dyspneic, ill-appearing, with an elevated oral temperature and respiratory rate (39.3[degrees]C and 56 breaths/min, respectively). She required assistance to walk. She had no palpable lymph nodes. A pulmonary examination showed marked chest indrawing and bilateral coarse crepitations. She was first treated 29 h after illness onset at the local health center, where she received chloramphenicol, 2 g intravenously as a single bolus, and doxycycline, 100 mg orally.

On her arrival at Nyapea Hospital, a grossly bloody sputum sample was obtained (Figure 1A). Because hospital staff were unaware of her previous treatment, she was retreated with chloramphenicol, 1 g intravenously, given 1 h and 45 min after her initial dose. She continued treatment with chloramphenicol, 1 g intravenously every 6 h for 48 h, then 750 mg every 6 h (10 days of intravenous treatment). She was discharged at day 10 and received oral chloramphenicol, 750 mg every 6 h for 8 additional days. On discharge, she was able to walk 1 mile to her home from the nearest road but with difficulty and shortness of breath. Three weeks after being discharged, she reported having returned to all usual activities including subsistence farming.

[FIGURE 1 OMITTED]

A series of 3 frontal chest radiographs taken on days 2, 3, and 18 of illness demonstrated bilateral airspace disease, predominantly in lower lung zones, with bilateral (right > left) pleural effusions without evidence of hilar or mediastinal lymphadenopathy (Figure 2). Findings were consistent with multilobar pneumonia with progressive diminution in airspace disease and pleural effusions over time.

[FIGURE 2 OMITTED]

Presence of Y. pestis in the surviving patient's sputum was verified by positive PCR results for genes on all 3 of the Y. pestis plasmids (Figure 1B), and DFA showing classic fluorescent staining halos of bacteria with Y. pestis-specific antibody (Figure 1C). Two handheld assays also detected Y. pestis antigen in the sputum. The sputum, which was obtained 1.5 h after her first antimicrobial drug dose, stored overnight without refrigeration, and transported the next day to the central laboratory (6 h in transport), did not yield Y. pestis on bacterial culture. A complete blood count at illness day 20 was within normal limits. Antibody to Y. pestis was not detected in serum from acute-phase blood samples. The patient declined to provide a sample for convalescent-phase serologic testing at a follow-up visit 3 weeks after discharge. The other 3 case-patients were already buried when the outbreak was reported; therefore, autopsies and laboratory verification of their plague diagnoses were not attempted.

Contact Tracing and Prophylaxis

Close contacts of index patients A1 and B1 are described in the Appendix Table (available from http ://www.cdc.gov/ncidod/EID/vol12no03/05-1051_app.htm). These contacts were not given antimicrobial drug prophylaxis because >1 week had passed since the index patients' deaths when the outbreak was reported. Twenty-five persons had direct contact with either patient (i.e., touched) after onset of cough productive of bloody sputum and before death, but only the 2 primary caregivers became ill (attack rate 2/25, 8%).

Examples of these index patients' close contacts include the following. Patient A1 slept in the same bed as her husband and 1.5-year-old daughter in a 1.8 x 3.1 x 2.0m bedroom the night before her death. The night before index patient B 1 's death, he slept in the same bed as his 6-yearold daughter until the early morning, when his wife noted he was very ill and coughing bloody sputum. His daughter then moved to a straw mat on the floor of the 4 x 4 x 1.6 m windowless 1-room house with her mother and 3 siblings, who had been sleeping there. Their heads were [approximately equal to] 1.8 m from their father's.

On index patient B1's last day, he was placed in a chair strapped on the back of a bicycle and transported 18 km to obtain medical care at several clinics. His 3 brothers who held him upright during this trip remained well without prophylaxis. In addition, [approximately equal to] 200 persons attended the 2 index patients' funerals; [approximately equal to] 75 persons touched the blanket that wrapped index patient B1's body, the same blanket that was used during the patient's final days of illness. No contacts used masks, gloves, or any other form of respiratory protection.

All identified close contacts of caregivers A2 and B2 received chemoprophylaxis (3 days of cotrimoxazole, 960 mg orally, twice a day), including 14 members of caregiver A2's family compound, 8 members of caregiver B2's family compound, and 4 healthcare providers who rode without masks in the ambulance with caregiver B2. Prophylaxis was initiated 4 days after caregiver A2's death, 2 days after caregiver B2's treatment initiation, and on the day of the ambulance ride, respectively. Additionally, local health authorities gave prophylaxis to 200 attendees of caregiver A2's funeral on the day of the funeral, which took place the morning after A2's death, the same day the outbreak was reported.

Community Surveillance

No additional pneumonic plague cases were identified during December and in the weeks after the outbreak report. However, through active surveillance we identified 3 probable bubonic plague patients who came to the subcounty's local health center in the first half of January, an increase from a baseline of 0 cases per month in the preceding 3 months. In addition, during the investigation in late December and early January, several villages in the subcounty reported rat deaths, and both index patients' families reported finding dead rats in their family compounds before the index patients' illness onset.

Discussion

We report 4 pneumonic plague cases involving 2 instances of person-to-person transmission. Even without appropriate treatment, the 2 index patients survived [greater than or equal to] 1 week. The index patients transmitted pneumonic plague, likely in their final hours of life, to only their primary caregivers, despite numerous other close contacts. This transmission pattern is compatible with respiratory droplet transmission rather than transmission by aerosols (droplet nuclei). Furthermore, only a few close contacts, who were all within droplet range, became ill. Primary pneumonic plague developed in the primary caregivers, who displayed a more fulminant clinical course. However, 1 survived without residual functional limitation after chloramphenicol treatment initiated 29 h after illness onset, which is later than commonly thought useful (11,12,14).

We identified 23 close contacts of the 2 index patients who remained well without antimicrobial drug prophylaxis or other form of protection, including 3 family members who slept in the same bed and many persons who slept with their heads at a distance <2m from the coughing plague patient. Some published literature describes pneumonic plague as highly contagious (9,12) through aerosols (droplet nuclei) (13). However, other researchers have reported that transmission requires prolonged close contact at the end stage of illness (2,18,19), which is consistent with respiratory droplet transmission (1,20). This investigation supports the latter view. Furthermore, droplet range is usually [less than or equal to] 3 feet (21), and all identified close contacts were well within that proximity to an index patient, but few (8%) became ill. Transmission likely occurred on the index patients' final day of life, given the 5-day interval until caregiver symptom onset after the index patients' death (incubation period usually 2-4 days, range 1-6) (2,19). Consistent with our findings, Gani and Leach's review of pneumonic plague outbreaks reported an average 1.3 pneumonic plague transmissions to other persons per pneumonic plague case (22). An investigation of a larger outbreak in Madagascar that used serologic testing to confirm plague infections also reported an attack rate among close contacts similar to ours (8.4%), although a definition of close contacts was not reported (23).

Our patients' clinical course provides clues to why pneumonic plague patients usually infect few persons and why, for example, an air travel-associated outbreak would be unlikely. Our case-patients were visibly short of breath, coughing grossly bloody sputum, and barely ambulatory before transmitting the disease. Thus, when patients are substantially contagious, they are unlikely to be traveling by air and, if so, would appear ill enough to alarm nearby passengers. In most settings, persons this ill are at home or in the hospital. Recent reviews support this observation because most reported pneumonic plague transmissions involve family, friends, or medical professionals caring for ill persons at home or in the hospital (2,22).

A current IDSA summary on Y. pestis as a bioterrorism agent notes, "in the absence of early therapy (i.e., within the first 24 h), death occurs from overwhelming sepsis" (14). This follows Butler's widely cited reviews, which state that pneumonic plague is "invariably fatal" if treated >20-24 h after illness onset (11,12) and cite the 1956 report of McCrumb et al. (24). More recent reviews (25) and other literature (26,27) indicate that survival is possible even when treatment is initiated after 24 h, consistent with caregiver B2's survival. This caregiver received chloramphenicol, the only parenteral drug designated as a national standard plague treatment in Uganda (28), 29 h after illness onset, and survived without supportive care (i.e., mechanical ventilation or oxygen therapy). In the United States, chloramphenicol is a second- or third-line plague treatment (1,29) because no randomized clinical trials have been conducted to document its comparability with accepted treatments and because it has potential hematologic side effects (1). Although caregiver B2 received supratherapeutic doses because of a communication error, experienced Ugandan clinicians report success treating plague, including pneumonic plague, with chloramphenicol, 500 mg intravenously every 6 h (30).

Clinical diagnosis of pneumonic plague is challenging, particularly without lymphadenopathy. Even in this plague-endemic area these cases were not suspected to be plague until an investigation was initiated after the third death. All 4 cases had 1 classic pneumonic plague feature: productive cough progressing to grossly bloody sputum (2,18,19). In plague-endemic regions, respiratory illnesses <1 week in duration with bloody or blood-tinged sputum should prompt consideration of a pneumonic plague diagnosis and empiric antimicrobial drug treatment for plague. Routine chest radiographs cannot be expected to establish a pneumonic plague diagnosis. The chest radiographs of surviving caregiver B2 were consistent with but not uniquely diagnostic for primary pneumonic plague. As with the few other published radiographs of primary pneumonic plague patients (1,24,27,31-33), these radiographic findings alone would not prompt clinicians to consider pneumonic plague without a preexisting clinical suspicion.

In our cluster, primary pneumonic plague (direct airway infection) progressed rapidly to life-threatening illness. In contrast, respiratory symptoms developed later in illness for the apparent secondary pneumonic plague patients, consistent with hematogenous spread from an alternate site of infection initiation, and their symptoms progressed more slowly. The more fulminant clinical course of primary pneumonic plague could help differentiate primary versus secondary pneumonic plague in naturally occurring outbreaks and pneumonic plague suspected of being caused by an intentional bacterial release because aerosol exposure would result in primary pneumonic plague. Time course of clinical progression can be established retrospectively from history alone, in contrast to lymphadenopathy (a bubo), which can also help differentiate primary and secondary pneumonic plague but requires a thorough physical examination. A bubo indicates that pneumonic plague is most likely secondary to a primary bubonic plague infection (14).

Upon hearing of 4 cases in close proximity, our initial assumption was these cases were linked. However, closer investigation demonstrated that the second patient became ill before the first patient developed cough, and these 2 patients had no apparent contact during the week before the second patient's illness onset. They lived within 2 km of each other but were from different villages and tribal backgrounds. This coincidence indicates the importance of detailed contact investigations before pneumonic plague cases are declared linked in areas with ongoing epizootics. The cluster is likely explained by the annual epizootic reaching the area and difficulty diagnosing pneumonic plague. Because the 2 index patients lived near each other, they were likely both exposed to the same epizootic (i.e., plague-infected rats and fleas). Since their illnesses went unrecognized and were not appropriately treated, the patients each transmitted their infection to their caregivers, creating this 4-case cluster.

Among the investigation's limitations, we depended on family members' recall for information on deceased patients' symptoms and activities. However, we believe multiple family member interviews and rapid investigation initiation minimized information loss. Another limitation was our inability to culture Y. pestis from the surviving patient's sputum, which likely resulted from administration of an antimicrobial drug before sputum collection and suboptimal specimen storage and transport. However, we verified plague infection by laboratory analysis of this sputum sample, including amplification of all 3 targeted plague plasmids by PCR and visualization of numerous bacteria with classic halos of Y. pestis by DFA staining. Additionally, the sputum tested strongly positive with both Y. pestis antigen dipsticks. Finally, we could not verify all cases through laboratory analysis because 3 case-patients had been buried by the time the outbreak was reported. However, high death rate, fulminant clinical course, laboratory verification for the surviving case, and clinical symptoms were consistent with plague. The concomitant bubonic plague increase and reports of rat deaths provide additional support that plague was endemic during this outbreak.

In conclusion, this investigation illustrates the clinical course of pneumonic plague, contrasts secondary and primary disease, and shows the relatively low communicability of pneumonic plague even with numerous close contacts. This information should guide bioterrorism response planning and the public health response to naturally occurring pneumonic plague outbreaks.

Acknowledgments

We thank David Dennis for critical review of and useful suggestions on an earlier version of this report; and Simon Okiria, Rose Namaganda, Robert Downing, the staff of Kango Health Center, Julie Magri, Bryce Ricken; Paul Mead, Jim Hadler, Matt Cartter, and Bartholomew Keogh for their assistance during this investigation.

This investigation was conducted as part of the routine duties of the authors without special funding or grant support. CDC and the Ugandan Ministry of Health were conducting a clinical trial of plague treatment in Uganda at the time of this investigation, which was supported by the US Food and Drug Administration through an interagency agreement.

Dr Begier was an Epidemic Intelligence Service officer with CDC at the time of this investigation. She is now medical director of the Bureau of HIV/AIDS Prevention and Control at the New York City Department of Health and Mental Hygiene. Her research interests include outbreak investigation and disease surveillance.

References

(1.) Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA. 2000;283:2281-90.

(2.) Kool JL. Risk of person-to-person transmission of pneumonic plague. Clin Infect Dis. 2005;40:1166-72.

(3.) Wu L-T, Chun JWH, Pollitzer R. Plague: a manual for medical and public health workers. Shanghai: The Mercury Press; 1936.

(4.) Inglesby TV, Grossman R, O'Toole T. A plague on your city: observations from TOPOFF. Clin Infect Dis. 2001;32:436-45.

(5.) US Department of Homeland Security. Transcript of background briefing with senior DHS officials on TOPOFF 3. 2005 Apr 8. [cited 2005 May 19]. Available from http://www.dhs.gov/dhspublic/display?content=4444

(6.) Fritz CL, Dennis DT, Tipple MA, Campbell GL, McCance CR, Gubler DJ. Surveillance for pneumonic plague in the United States during an international emergency: a model for control of imported emerging diseases. Emerg Infect Dis. 1996;2:30-6.

(7.) Ramalingaswami V. Psychosocial effects of the 1994 plague outbreak in Surat, India. Mil Med. 2001;166(12 Suppl):29-30.

(8.) Post T, Clifton T, Mazumdar S, Cowley G, Raghavan S. The plague of panic. Newsweek. 10 Oct 1994:40-1.

(9.) Cowling P, Moss P. Infectivity of pneumonic plague. BMJ. 1994;309:1369.

(10.) Nebehay S. World Health Organization. Thousands flee as plague kills 61 in Congo. Reuters Health. 2005 Feb 18. [cited 2005 Mar 29]. Available from http://www.promedmail.org (archive no. 20050218.0537).

(11.) Butler T. Yersinia species, including plague. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious disease. 5th ed. Philadelphia: Churchill Livingstone; 2000. p. 2406-14.

(12.) Butler TC. Plague and other Yersinia infections. In: Greenough WB III, Merigan TC, editors. Current topics in infectious disease. New York: Plenum; 1983. p. 178-182.

(13.) Levison ME. Lessons learned from history on mode of transmission for control of pneumonic plague. Curr Infect Dis Rep. 2000;2:269-71.

(14.) Infectious Diseases Society of America. Plague medical summary. 2005 Mar 24. [cited 2005 Mar 31]. Available from http://www.idsociety.org/Template.cfm? Section=Bioterrorism&CONTENTID= 12442&TEMPLATE=/ContentManagement/ContentDispl ay.cfm

(15.) Bahmanyar M, Cavanaugh DC. Plague manual. Geneva: World Health Organization; 1976. p.26-8.

(16.) Engelthaler DM, Gage KL, Montenieri JA, Chu M, Carter LG. PCR detection of Yersinia pestis in fleas: comparison with mouse inoculation. J Clin Microbiol. 1999;37:1980-4.

(17.) Chu MC. Laboratory manual of diagnostic tests. Geneva: World Health Organization; 2000.

(18.) Pollitzer R. Plague. Geneva: World Health Organization; 1954.

(19.) Wu L-T. A treatise on pneumonic plague. Geneva: League of Nations; 1926.

(20.) Inglesby TV, Henderson DA, O'Toole T, Dennis DT. Safety precautions to limit exposure from plague-infected patients. JAMA. 2000;284:1648-9.

(21.) Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1996; 17:53-80.

(22.) Gani R, Leach S. Epidemiologic determinants for modeling pneumonic plague outbreaks. Emerg Infect Dis. 2004;10:608-14.

(23.) Ratsitorahina M, Chanteau S, Rahalison L, Ratsifasoamanana L, Boisier P. Epidemiological and diagnostic aspects of the outbreak of pneumonic plague in Madagascar. Lancet. 2000;355:111-3.

(24.) McCrumb FR Jr, Mercier S, Robic J, Bouillat M, Smadel JE, Woodward TE, et al. Chloramphenicol and terramycin in the treatment of pneumonic plague. Am J Med. 1953;14:284-93.

(25.) Butler T, Dennis DT. Yersinia species, including plague. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious disease. Volume 2. 6th ed. Philadelphia: Churchill Livingstone; 2004. p. 2690-700.

(26.) Gage KL, Dennis DT, Orloski KA, Ettestad P, Brown TL, Reynolds PJ, et al. Cases of cat-associated human plague in the Western US, 1977-1998. Clin Infect Dis. 2000;30:893-900.

(27.) Cramer C, Christensen B. Pneumonic plague in a 15-year-old Utah girl. J Emerg Nurs. 1995;21:491-3.

(28.) Uganda Essential Drugs Manual. Entebbe, Uganda: Ministry of Health Uganda Essential Drugs Management Programme; 1997.

(29.) Gilbert DN, Moellering RC, Sande MA, Eliopoulos GM, Sande MA. Sanford guide to antimicrobial therapy, 2004 pocket edition. 34th ed. Hyde Park (VT): Antimicrobial Therapy, Inc.; 2004.

(30.) Orochi Orach S. Plague outbreaks: the gender and age perspective in Okoro County, Nebbi District, Uganda. July 2003. Nebbe, Uganda: Agency for Accelerated Regional Development; 2003..

(31.) Burmeister RW, Tigertt WD, Overholt EL. Laboratory-acquired pneumonic plague, report of a case and review of previous cases. Ann Intern Med. 1962;56:789-800.

(32.) Doll JM, Zeitz PS, Ettestad P, Bucholtz AL, Davis T, Gage K. Cattransmitted fatal pneumonic plague in a person who traveled from Colorado to Arizona. Am J Trop Med Hyg. 1994;51:109-14.

(33.) Werner SB, Weidmer CE, Nelson BC, Nygaard GS, Goethals RM, Poland JD. Primary plague pneumonia contracted from a domestic cat at South Lake Tahoe, California. JAMA. 1984;251:929-31.

Address for correspondence: Elizabeth M. Begier, Bureau of HIV/AIDS Prevention and Control, New York City Department of Health and Mental Hygiene, 346 Broadway, Room 701-707, New York, NY 10013, USA; fax: [phone]; email: [e-mail]

Elizabeth M. Begier, * Gershim Asiki, ([dagger]) Zaccheus Anywaine, ([dagger]) Brook Yockey, ([double dagger]) Martin E. Schriefer, ([double dagger]) Philliam Aleti, ([section]) Asaph Ogen-Odoi, ([section]) J. Erin Staples, * ([double dagger]) Christopher Sexton, ([double dagger]) Scott W. Bearden, ([double dagger]) and Jacob L. Kool ([double dagger])

* Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ([dagger]) Nyapea Hospital, Nebbi District, Uganda; ([double dagger]) Centers for Disease Control and Prevention, Fort Collins, Colorado, USA; and ([section]) Uganda Virus Research Institute, Entebbe, Uganda

Table. National history and timing of symptom onset for index patients
(secondary pneumonic plague) versus caregiver-patients (primary
pneumonic plague), Uganda, December 2004

                                          Symptom onset by day of
                                                 illness *

                                                1             2
                           Patient
Symptoms ([dagger])   ([double dagger])     AM      PM   AM     PM

Fever/chills                  A1             X
                              B1             X
                              A2             O
                              B2             O
Headache                      A1             X
                              B1             X
                              A2             O
                              B2             O
Lymphadenopathy               A1
                              B1          Unknown
                              A2          None
                              B2          None
Weakness                      A1
                              B1                                 X
                              A2             O
                              B2             O
Cough                         Al
                              B1
                              A2             O
                              B2                    O
Chest pain                    A1
                              B1
                              A2             O
                              B2             O
Productive cough              A1
                              B1
                              A2             O
                              B2                    O
Bloody sputum                 A1
                              B1
                              A2                                 O
                              B2                    O
Shortness of breath           Al
                              B1
                              A2                         O
                              B2                         O
Nonambulatory                 A1
                              B1
                              A2
                              B2          Never
Death/effective               A1
treatment                     B1
                              A2
                              B2                               O (#)

                                             Symptom onset by day of
                                                    illness *

                                               3                  4
                           Patient
Symptoms ([dagger])   ([double dagger])   AM        PM         AM   PM

Fever/chills                  A1
                              B1
                              A2
                              B2
Headache                      A1
                              B1
                              A2
                              B2
Lymphadenopathy               A1          X
                              B1
                              A2
                              B2
Weakness                      A1                               X
                              B1
                              A2
                              B2
Cough                         Al
                              B1                                    X
                              A2
                              B2
Chest pain                    A1
                              B1
                              A2
                              B2
Productive cough              A1
                              B1
                              A2
                              B2
Bloody sputum                 A1
                              B1
                              A2
                              B2
Shortness of breath           Al
                              B1
                              A2
                              B2
Nonambulatory                 A1
                              B1
                              A2          O
                              B2
Death/effective               A1
treatment                     B1
                              A2                     O
                                               ([paragraph])
                              B2

                                            Symptom onset by day of
                                                   illness *

                                             5          6
                           Patient
Symptoms ([dagger])   ([double dagger])   AM   PM   AM       PM

Fever/chills                 A1
                             B1
                             A2
                             B2
Headache                     A1
                             B1
                             A2
                             B2
Lymphadenopathy              A1
                             B1
                             A2
                             B2
Weakness                     A1
                             B1
                             A2
                             B2
Cough                        A1           X
                             B1
                             A2
                             B2
Chest pain                   A1           X
                             B1                               X
                                                         ([section])
                             A2
                             B2
Productive cough             A1
                             B1           X
                             A2
                             B2
Bloody sputum                A1
                             B1                X
                             A2
                             B2
Shortness of breath          Al
                             B1                     X
                             A2
                             B2
Nonambulatory                A1
                             B1
                             A2
                             B2
Death/effective              A1
treatment                    B1
                             A2
                             B2

                                            Symptom onset by day of
                                                   illness *

                                               7                  8
                           Patient
Symptoms ([dagger])   ([double dagger])   AM        PM         AM   PM

Fever/chills                 A1
                             B1
                             A2
                             B2
Headache                     A1
                             B1
                             A2
                             B2
Lymphadenopathy              A1
                             B1
                             A2
                             B2
Weakness                     A1
                             B1
                             A2
                             B2
Cough                        Al
                             B1
                             A2
                             B2
Chest pain                   A1
                             B1
                             A2
                             B2
Productive cough             A1           X
                             B1
                             A2
                             B2
Bloody sputum                A1                                X
                             B1
                             A2
                             B2
Shortness of breath          Al
                             B1
                             A2
                             B2
Nonambulatory                A1
                             B1           X
                             A2
                             B2
Death/effective              A1
treatment                    B1                      X
                                               ([paragraph])
                             A2
                             B2

                                          Symptom onset by day of
                                                 illness *

                                                   9
                           Patient
Symptoms ([dagger])   ([double dagger])      AM        PM

Fever/chills                 A1
                             B1
                             A2
                             B2
Headache                     A1
                             B1
                             A2
                             B2
Lymphadenopathy              A1
                             B1
                             A2
                             B2
Weakness                     A1
                             B1
                             A2
                             B2
Cough                        Al
                             B1
                             A2
                             B2
Chest pain                   A1
                             B1
                             A2
                             B2
Productive cough             A1
                             B1
                             A2
                             B2
Bloody sputum                A1
                             B1
                             A2
                             B2
Shortness of breath          A1              X
                             B1
                             A2
                             B2
Nonambulatory                A1              X
                             B1
                             A2
                             B2
Death/effective              A1                         X
treatment                                         ([paragraph])
                             B1
                             A2
                             B2

* X, secondary pneumonic plague index patient, O, primary pneumonic
plague caregiver-patient. AM, symptom first appeared between midnight
and noon; PM, symptom first appeared between noon and midnight.

([dagger]) Additional symptoms: caregiver A2 had a sore throat and
ulcerative pharyngitis. Caregiver B2 had a burning back pain that
started at the time of illness onset. Index patients A1 and B1 both
had vomiting, and B1 also had diarrhea.

([double dagger]) Cases are listed by time of onset: 12/9 (A1), 12/13
(B1), 12/23 (A2), 12/25 (B2). Caregiver A2 reported her husband was
ill about midday on 12/23, but symptoms might have started earlier.
Caregiver A2 was index patient A1's mother and her primary caregiver
during her illness. Caregiver B2 was index patient B1's sister and his
primary caregiver during his illness.

([section]) Patient B1 first reported to family members severe chest
pain on day 6 of illness but might have had mild chest pain earlier.

([paragraph]) Death.

(#) Treatment and survival.